ECEthan Cowan

Ethan Cowan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ethan Cowan has a total of 102 co-authors. Here are the top co-authors by number of shared publications:

  • Jeanmarie Perrone

    University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, United States of America

    5 shared publications
  • Yvette Calderon

    Icahn School of Medicine at Mount Sinai

    5 shared publications
  • Andrew Herring

    Department of Emergency Medicine Highland General Hospital‐Alameda Health System Oakland California USA

    4 shared publications
  • Erick Eiting

    Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, New York, New York

    4 shared publications
  • Ryan McCormack

    Ronald O. Perelman Department of Emergency Medicine New York University Grossman School of Medicine New York New York USA

    4 shared publications
  • Kathryn Hawk

    Department of Emergency Medicine Yale School of Medicine New Haven Connecticut USA

    3 shared publications

Latest Publications

  • From Law to Practice, Emergency Department Leaders' Experiences With Universal HIV Testing in New York City: A Qualitative Research Brief

    by Christine Tagliaferri Rael, Stefanie Mayorga, Tatiana Gonzalez-Argoti, Lilian Ha, Samantha Stonbraker, Yvette Calderon, Susie Hoffman, Ethan Cowan, Laurie J. Bauman, Joanne E. Mantell

    Was not provided for this article.

  • Open Access

    Implementation facilitation improves readiness for emergency department-initiated buprenorphine to treat opioid use disorder

    by Tania Strout, James Dziura, Tyler W. Barrett, Ethan Cowan, Kathryn F. Hawk, Andrew A. Herring, Jacob Manteuffel, Shara Martel, Patricia H. Owens, Ryan P. McCormack, et al.


  • Open Access

    Drug Use After Emergency Department‐Initiated Injectable Buprenorphine: A Secondary Analysis of the ED ‐ INNOVATION Ancillary Safety and Feasibility Trial

    by Ethan Cowan, Gail D'ONofrio, Jeanmarie Perrone, Erik Anderson, James Dziura, Kathryn Hawk, Andrew Herring, Ryan McCormack, Manali Phadke, Elizabeth A. Samuels, et al.

    Study Objective: To characterize opioid and nonopioid drug use in the week following emergency department (ED)‐initiated extended‐release buprenorphine (XR‐BUP) treatment using both self‐reported data and urine drug screens (UDS). Methods: This study uses data collected during a nonrandomized clinical trial of patients with untreated opioid use disorder (OUD), testing the safety and feasibility of initiating XR‐BUP in patients presenting with minimal to mild withdrawal. The study was conducted from July 2020 to May 2023 across four urban academic EDs in the Northeast, Mid‐Atlantic, and Pacific regions of the United States. A total of 100 participants, 18 years or older with OUD defined by DSM‐5 criteria, a clinical opiate withdrawal scale (COWS < 8), and a positive opioid urine screen were included. Individuals with recent MOUD treatment, presentation for overdose, or concurrent methadone use were excluded. All participants received a single subcutaneous injection of 24 mg XR‐BUP (CAM2038) during their ED visit. The primary outcomes were self‐reported daily opioid and nonopioid drug use over 7 days postinjection using daily Qualtrics surveys and UDS results on day 7. Results: Among participants who received XR‐BUP and completed daily surveys, 98% reported at least one opioid‐free day, and 63% reported no opioid use across all 7 days. Day 7 UDS results showed decreased detection of opioids, stimulants, and benzodiazepines. Reported polysubstance use also declined over the observation period. Conclusions: ED‐initiated XR‐BUP was associated with substantial reductions in opioid and polysubstance use during the first week post‐discharge, supporting its role in early overdose risk mitigation and highlighting its value as an ED‐based intervention for opioid use disorder. Trial Registration: ClinicalTrials.gov Identifier: NCT03658642

  • Emergency Department (ED) Leaders' Perspectives on Offering HIV Preexposure Prophylaxis (PrEP) in New York City EDs: A Qualitative Study

    by Christine Tagliaferri Rael, Stefanie Mayorga, Tatiana Gonzalez-Argoti, Lilian Ha, Samantha Stonbraker, Yvette Calderon, Susie Hoffman, Ethan Cowan, Laurie J. Bauman, Joanne E. Mantell

    Offering preexposure prophylaxis (PrEP) in nontraditional settings, such as emergency departments (EDs), may be an opportunity to connect HIV-vulnerable people with PrEP. Our study aimed to identify the perspectives of N = 10 ED leaders on initiating PrEP in EDs in New York City. Leaders completed 30-min, audio-recorded, in-depth interviews through Zoom, covering challenges/benefits to offering PrEP in EDs, and how potential programs could be set up and managed. From interviews, we formed three key discussion points for designing and implementing PrEP in EDs: (a) ED leadership views PrEP as important, but resource/contextual barriers pose an implementation challenge, (b) interventions must leverage familiar clinical pathways for implementation and minimize burden to provider time/ED resources, (c) using telehealth and patient navigators to implement PrEP in ED interventions could overcome the challenges but may not be available everywhere. Building on relationships with referral partners could be a viable alternative in resource constrained settings.

  • Open Access

    Sex disparities in chlamydia and gonorrhea treatment in U.S. adult emergency departments: A systematic review and meta‐analysis

    by Rachel E. Solnick, Rahi Patel, Ethan Chang, Carmen Vargas‐Torres, Maaz Munawar, Carlin Pendell, Judith E. Smith, Ethan Cowan, Keith E. Kocher, Roland C. Merchant

    Background: Empiric antibiotic treatment for gonorrhea (GC) and chlamydia (CT) is common in U.S. emergency departments (EDs) due to the delayed availability of test results. Local studies have identified sex‐based disparities in sexually transmitted infection (STI) care, with females potentially receiving less empiric treatment than males. This study evaluates how STI treatment aligns with laboratory‐confirmed results to quantify potential overtreatment and undertreatment rates and investigates sex differences for these outcomes.Methods: We conducted a preregistered (PROSPERO #241429) systematic review and meta‐analysis of studies published between January 2010 and January 2025 in U.S. EDs, excluding studies conducted exclusively in pediatric settings. Searches were performed in Medline, Cochrane, Embase, Scopus, Web of Science, CINAHL, and PsycINFO. Data from 19 studies encompassing 32,593 tested patients were analyzed using a random‐effects model to calculate pooled estimates. Primary outcomes included GC/CT positivity, empiric treatment rates, and discordance between treatment and test results stratified by sex.Results: Overall GC/CT positivity was 14% (95% confidence interval [CI] 12%–16%): 11% (95% CI 8%–14%) in females and 25% (95% CI 23%–26%) in males. Antibiotics were given to 46% (95% CI 38%–54%) of patients: 31% (95% CI 24%–37%) of females and 73% (95% CI 65%–80%) of males. Among patients with negative test results, 38% (95% CI 30%–47%) received antibiotics (i.e., potential overtreatment): 27% (95% CI 20%–34%) of females and 64% (95% CI 55%–73%) of males. Conversely, 39% (95% CI 31%–46%) of laboratory‐positive patients did not receive antibiotics (i.e., potential undertreatment): 52% (95% CI 46%–57%) of females and 15% (95% CI 12%–17%) of males.Conclusions: Significant sex‐based disparities exist in ED empiric antibiotic treatment for GC/CT. Females were 3.5 times more likely than males to be potentially undertreated. These findings underscore the need for targeted interventions to reduce disparities and improve treatment accuracy. Interpretation is limited by study heterogeneity and incomplete sex‐specific data.


  • Open Access

    HIV Preexposure Prophylaxis Service Delivery Models for Emergency Departments: A Qualitative Study

    by Ethan Cowan, Susie Hoffman, Laurie J Bauman, Yvette Calderon, Tatiana Gonzalez-Argoti, Christine T Rael, Jonathan Porter, Joanne E Mantell

    Background: Oral preexposure prophylaxis (PrEP) effectively prevents HIV but is underutilized in the United States, particularly among populations with higher incidence of HIV. Emergency departments (EDs), which often care for medically underserved individuals, could play a key role in expanding PrEP access. However, integrating PrEP into ED workflows presents challenges. Methods: This qualitative study involved interviews with 22 stakeholders from 15 EDs and 4 sexual health clinics across the United States. Participants included ED leaders, providers, and navigators. The data were analyzed using a PrEP care cascade model, focusing on provider buy-in, patient identification, education, PrEP initiation, and linkage to care. Results: Key barriers included limited provider knowledge, ED priorities focused on acute care, and the reliance on grant funding without long-term plans for sustainability. Successful programs relied on ED champions to advocate for PrEP and improve staff engagement. Some EDs offered same-day PrEP prescriptions or starter packs, which improved uptake, but most relied on referrals and had low follow-up rates. Patient identification strategies, such as using navigators or risk scores, varied across sites. Education was often led by ancillary staff, as ED providers had limited time and training. Sustainability remained a major challenge, as most programs were dependent on short-term funding. Conclusions: To expand PrEP access in EDs, it is essential to address systemic barriers, improve provider training and establish sustainable funding models. Streamlined workflows, dedicated staff, and targeted interventions can help EDs play a more active role in HIV prevention.


  • Open Access

    A Randomized Controlled Trial of HIV Pre-Exposure Prophylaxis Provision in the Emergency Department (PrEPPED)

    by Ethan Cowan, Erick Eiting, Clare O'BRien-Lambert, Jacqueline Ryder, Yvette Calderon


  • Open Access

    Emergency department–initiated oral naltrexone for patients with moderate to severe alcohol use disorder: A pilot feasibility study

    by Ethan Cowan, Clare O'Brien‐Lambert, Erick Eiting, Edward Bull, Jacqueline Ryder, Yvette Calderon, Edwin Salsitz

    Objectives: Alcohol use disorder (AUD) is the most common substance use disorder in the United States. Despite availability of four FDA‐approved medications, fewer than 10% of patients are prescribed medication. This study aimed to evaluate the impact and feasibility of emergency department (ED)‐initiated oral naltrexone in patients with moderate to severe AUD.Methods: This was a prospective, single‐arm, open‐label, nonrandomized clinical trial conducted a single ED. Consenting participants were adults with moderate to severe AUD who were provided a single 50‐mg dose of oral naltrexone, a 14‐day starter pack of naltrexone, and referral for treatment. Follow‐up was conducted at 14 and 30 days post–ED visit. The primary outcome was engagement in formal addiction treatment. Secondary outcomes included alcohol consumption, craving, quality‐of‐life measures, satisfaction, and safety.Results: Of 761 patients screened, 21 enrolled and received at least one dose of naltrexone. At 14 days, 29% were engaged in treatment, increasing to 33% at 30 days. There was a decrease in the mean (±SD) number of drinks per day from 5.20 (±4.67) at baseline to 2.23 (±4.35) during the follow‐up period (p = 0.078). There was a decrease in alcohol craving scores, with median scores dropping from 19 at baseline to 8.27 during the follow‐up period (p < 0.001). Quality‐of‐life measures improved, with a statistically significant increase in the reported number of healthy days (p = 0.006) and decrease in depressive symptoms (p < 0.001). Reported side effects were mild and satisfaction with the screening process was high.Conclusions: ED‐initiated oral naltrexone is feasible and acceptable for patients with moderate to severe AUD. While engagement in treatment was moderate, significant reductions in alcohol craving and improvements in quality of life suggest potential benefits. Further research is warranted to confirm these findings.


  • Open Access

    Three Pilot Randomized Controlled Trials Evaluating a Persuasive Health Communication Intervention for Adult Emergency Department Patients Declining HIV/HCV Testing

    by Roland C. Merchant, Melissa A. Clark, Michael P. Carey, Tao Liu, George Loo, Ethan A. Cowan

    The Journal of Scientific Innovation in Medicine is an open access, international, peer reviewed journal covering the range of transformative scientific developments from the bench, to the bedside, and to local and global communities with emphasis on new concepts and paradigms in the prevention and treatment of human disease and the creation of human health. The mission of this journal is twofold. First, we advance an understanding of how to apply new technology, scientific discovery and innovative solutions in order to expand the frontiers of medicine and health. The journal welcomes research pertaining to diagnostic and therapeutic discovery from clinicians, scientists and practitioners as they discover new ways to prevent and treat diseases and illnesses. The journal also welcomes research on the impact of scientific discovery on health care systems, public health and population health including costs, value, applicability and social determinants of health. In addition, the journal solicits original papers exploring attitudes towards health care innovation, exploring health technology assessment and the effect of new technology on patients and communities. Second, we provide a mentored learning environment in transformative and sustainable scholarly communication. We welcome submissions of papers from students, residents and fellows papers including those building on accepted conference abstracts. We encourage trainees to publish their work originating from evidence-based research to our constructive peer review process. Our editorial team blends students, trainees, librarians, and faculty with a wide range of authorship and editorial expertise in order that we provide mentored peer review learning opportunities. Supported by the Icahn School of Medicine at Mount Sinai and its Gustave L. and Janet W. Levy Library, the journal does not charge author submission/publication/processing fees and the content is open for all readers. To learn more about how to get involved with our open journals on the Levy Library Press, contact Kris Alpi, Associate Dean of Libraries & Information Sciences.

  • Open Access

    Testing a persuasive health communication intervention (PHCI) for emergency department patients who declined rapid HIV/HCV screening: a randomised controlled trial study protocol

    by Roland C Merchant, Nancy Harrington, Melissa A Clark, Tao Liu, Jake Morgan, Ethan Cowan, Rachel Solnick, Benjamin Wyler

    Introduction Previous studies have shown that substantial percentages of emergency department (ED) patients in the USA recommended for HIV or hepatitis C (HCV) decline testing. Evidence-based and cost-effective interventions to improve HIV/HCV testing uptake are needed, particularly for people who inject drugs (PWIDs) (currently or formerly), who comprise a group at higher risk for these infections. We developed a brief persuasive health communication intervention (PHCI) designed to convince ED patients who had declined HIV/HCV testing to agree to be tested. In this investigation, we will determine if the PHCI is more efficacious in convincing ED patients to be tested for HIV/HCV when delivered by a video or in person, and whether efficacy is similar among individuals who currently, previously or never injected drugs. Methods and analysis We will conduct a multisite, randomised controlled trial comparing PHCIs delivered by video versus in person by a health educator to determine which delivery method convinces more ED patients who had declined HIV/HCV testing instead to be tested. We will stratify randomisation by PWID status (current, former or never/non-PWID) to permit analyses comparing the PHCI delivery method by injection-drug use history. We will also perform a cost-effectiveness analysis of the interventions compared with current practice, examining the incremental cost-effectiveness ratio between the two interventions for the ED population overall and within individual strata of PWID. As an exploratory analysis, we will assess if a PHCI video with captions confers increased or decreased acceptance of HIV/HCV testing, as compared with a PHCI video without captions. Ethics and dissemination The study protocol has been approved by the institutional review board of the Icahn School of Medicine. The results will be disseminated at international conferences and in peer-reviewed publications. Trial registration number NCT05968573.